Adverse effects include addiction, memory problems, paranoia, difficulty sleeping, teeth grinding, blurred vision, sweating, and a rapid heartbeat. Deaths have been reported due to increased body temperature and dehydration. Following use people often feel depressed and tired. MDMA acts primarily by increasing the activity of the neurotransmitters serotonin, dopamine, and noradrenaline in parts of the brain. It belongs to the substituted amphetamine classes of drugs and has stimulant and hallucinogenic effects.
MDMA is illegal in most countries and, as of 2018, has no approved medical uses. Limited exceptions are sometimes made for research. Researchers are investigating whether MDMA may assist in treating severe, treatment-resistant posttraumatic stress disorder (PTSD) with phase 3 clinical trials to look at effectiveness and safety expected to begin in 2018. In 2017, the FDA granted MDMA a breakthrough therapy designation[note 2] for PTSD, meaning that if studies show promise, a review for potential medical use could occur more quickly.
MDMA was first developed in 1912 by Merck. It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. MDMA is commonly associated with dance parties, raves, and electronic dance music. It is often sold mixed with other substances such as ephedrine, amphetamine, and methamphetamine. In 2016, about 21 million people between the ages of 15 and 64 used ecstasy (0.3% of the world population). This was broadly similar to the percentage of people who use cocaine or amphetamines, but lower than for cannabis or opioids. In the United States, as of 2017, about 7% of people have used MDMA at some point in their lives and 0.9% have used it in the last year.
In general, MDMA users report feeling the onset of subjective effects within 30 to 60 minutes of oral consumption and reaching peak effect at 75 to120 minutes, which then plateaus for about 3.5 hours. The desired short-term psychoactive effects of MDMA have been reported to include:
- Euphoria – a sense of general well-being and happiness
- Increased self-confidence, sociability, and perception of facilitated communication
- Entactogenic effects—increased empathy or feelings of closeness with others and oneself
- Dilated pupil
- Relaxation and reduced anxiety
- Increased emotionality
- A sense of inner peace
- Mild hallucination
- Enhanced sensation, perception, or sexuality
- Altered sense of time
The experience elicited by MDMA depends on the dose, setting, and user. The variability of the induced altered state is lower compared to other psychedelics. For example, MDMA used at parties is associated with high motor activity, reduced sense of identity, and poor awareness of surroundings. Use of MDMA individually or in small groups in a quiet environment and when concentrating, is associated with increased lucidity, concentration, sensitivity to aesthetic aspects of the environment, enhanced awareness of emotions, and improved capability of communication. In psychotherapeutic settings, MDMA effects have been characterized by infantile ideas, mood lability, and memories and moods connected with childhood experiences.
MDMA has been described as an "empathogenic" drug because of its empathy-producing effects. results of several studies show the effects of increased empathy with others. When testing MDMA for medium and high doses, it showed increased hedonic and arousal continuum. The effect of MDMA increasing sociability is consistent, while its effects on empathy have been more mixed.
MDMA is often considered the drug of choice within the rave culture and is also used at clubs, festivals, and house parties. In the rave environment, the sensory effects of music and lighting are often highly synergistic with the drug. The psychedelic amphetamine quality of MDMA offers multiple appeals to users in the rave setting. Some users enjoy the feeling of mass communion from the inhibition-reducing effects of the drug, while others use it as party fuel because of the drug's stimulatory effects. MDMA is used less often than other stimulants, typically less than once per week.
As of 2017[update], MDMA has no accepted medical indications. Before it was widely banned, it saw limited use in psychotherapy. A few psychotherapists continue to use MDMA in therapy despite the drug's legal status.
MDMA has become widely known as ecstasy (shortened "E", "X", or "XTC"), usually referring to its tablet form, although this term may also include the presence of possible adulterants or diluents. The UK term "mandy" and the US term "molly" colloquially refer to MDMA in a crystalline powder form that is thought to be free of adulterants. MDMA is also sold in the form of the hydrochloride salt, either as loose crystals or in gelcaps.
Partly due to the global supply shortage of sassafras oil—a problem largely assuaged by use of improved or alternative modern methods of synthesis—the purity of substances sold as molly have been found to vary widely. Some of these substances contain methylone, ethylone, MDPV, mephedrone, or any other of the group of compounds commonly known as bath salts, in addition to, or in place of, MDMA. Powdered MDMA ranges from pure MDMA to crushed tablets with 30–40% purity. MDMA tablets typically have low purity due to bulking agents that are added to dilute the drug and increase profits (e.g., lactose) and binding agents. Tablets sold as ecstasy sometimes contain 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA), other amphetamine derivatives, caffeine, opiates, or painkillers. Some tablets contain little or no MDMA. The proportion of seized ecstasy tablets with MDMA-like impurities has varied annually and by country. The average content of MDMA in a preparation is 70 to 120 mg with the purity having increased since the 1990s.
Acute adverse effects are usually the result of high or multiple doses, although single dose toxicity can occur in susceptible individuals. The most serious short-term physical health risks of MDMA are hyperthermia and dehydration. Cases of life-threatening or fatal hyponatremia (excessively low sodium concentration in the blood) have developed in MDMA users attempting to prevent dehydration by consuming excessive amounts of water without replenishing electrolytes.
The immediate adverse effects of MDMA use can include:
- Bruxism (grinding and clenching of the teeth)
- Increased wakefulness or insomnia
- Increased perspiration and sweating
- Increased heart rate and blood pressure
- Increased psychomotor activity
- Loss of appetite
- Nausea and vomiting
- Erectile dysfunction
- Visual and auditory hallucinations (rarely)
As of 2015[update], the long-term effects of MDMA on human brain structure and function have not been fully determined. However, there is consistent evidence of structural and functional deficits in MDMA users with high lifetime exposure. There is no evidence of structural or functional changes in MDMA users with only a moderate (<50 doses used and <100 tablets consumed) lifetime exposure. Nonetheless, MDMA in moderate use may still be neurotoxic. Furthermore, it is not clear yet whether "typical" users of MDMA (1 to 2 pills of 75 to 125 mg MDMA or analogue every 1 to 4 weeks) will develop neurotoxic brain lesions. Long-term exposure to MDMA in humans has been shown to produce marked neurodegeneration in striatal, hippocampal, prefrontal, and occipital serotonergic axon terminals. Neurotoxic damage to serotonergic axon terminals has been shown to persist for more than two years. Elevations in brain temperature from MDMA use are positively correlated with MDMA-induced neurotoxicity. However, most studies on MDMA and serotonergic neurotoxicity in humans focus on the heaviest users, those who consume more than seven times the average. It is therefore likely that no serotonergic neurotoxicity is present in most casual users. Adverse neuroplastic changes to brain microvasculature and white matter also occur in humans using low doses of MDMA. Reduced gray matter density in certain brain structures has also been noted in human MDMA users. Global reductions in gray matter volume, thinning of the parietal and orbitofrontal cortices, and decreased hippocampal activity have been observed in long term users. The effects established so far for recreational use of ecstasy lie in the range of moderate to severe effects for SERT[expand acronym] reduction.
Impairments in multiple aspects of cognition, including attention, learning, memory, visual processing, and sleep have been found in regular MDMA users. The magnitude of these impairments is correlated with lifetime MDMA usage and are partially reversible with abstinence. Several forms of memory are impaired by chronic ecstasy use; However, the effects for memory impairments in ecstasy users are generally small overall. MDMA use is also associated with increased impulsivity and depression.
Serotonin depletion following MDMA use can cause depression in subsequent days. In some cases, depressive symptoms persist for longer periods. Some studies indicate repeated recreational use of ecstasy is associated with depression and anxiety, even after quitting the drug. Depression is one of the main reasons for cessation of use.
At high doses, MDMA induces a neuroimmune response that, through several mechanisms, increases the permeability of the blood-brain barrier, thereby making the brain more susceptible to environmental toxins and pathogens.[page needed] In addition, MDMA has immunosuppressive effects in the peripheral nervous system and pro-inflammatory effects in the central nervous system.
MDMA is a moderately teratogenic drug (i.e., it is toxic to the fetus). In utero exposure to MDMA is associated with a neuro- and cardiotoxicity and impaired motor functioning. Motor delays may be temporary during infancy or long-term. The severity of these developmental delays increases with heavier MDMA use.
Approximately 60% of MDMA users experience withdrawal symptoms when they stop taking MDMA. Some of these symptoms include fatigue, loss of appetite, depression, and trouble concentrating. Tolerance to some of the desired and adverse effects of MDMA is expected to occur with consistent MDMA use. A 2007 analysis estimated MDMA to have a psychological dependence and physical dependence potential roughly three-fourths to four-fifths that of cannabis.
MDMA has been shown to induce ΔFosB in the nucleus accumbens. Because MDMA releases dopamine in the striatum, the mechanisms by which it induces ΔFosB in the nucleus accumbens are analogous to other dopaminergic psychostimulants. Therefore, chronic use of MDMA at high doses can result in altered brain structure and drug addiction that occur as a consequence of ΔFosB overexpression in the nucleus accumbens. MDMA is less addictive than other stimulants such as methamphetamine and cocaine. Compared with amphetamine, MDMA and its metabolite MDA are less reinforcing.
One study found approximately 15% of chronic MDMA users met the DSM-IV diagnostic criteria for substance dependence. However, there is little evidence for a specific diagnosable MDMA dependence syndrome because MDMA is typically used relatively infrequently.
There are currently no medications to treat MDMA addiction.
A 2007 UK study ranked MDMA 18th in harmfulness out of 20 recreational drugs. Rankings for each drug were based on the risk for acute physical harm, the propensity for physical and psychological dependency on the drug, and the negative familial and societal impacts of the drug. The authors did not evaluate or rate the negative impact of ecstasy on the cognitive health of ecstasy users (e.g. impaired memory and concentration).
MDMA overdose symptoms vary widely due to the involvement of multiple organ systems. Some of the more overt overdose symptoms are listed in the table below. The number of instances of fatal MDMA intoxication is low relative to its usage rates. In most fatalities, MDMA was not the only drug involved. Acute toxicity is mainly caused by serotonin syndrome and sympathomimetic effects. MDMA's toxicity in overdose may be exacerbated by caffeine, with which it is frequently cut in order to increase volume. A scheme for management of acute MDMA toxicity has been published focusing on treatment of hyperthermia, hyponatraemia, serotonin syndrome, and multiple organ failure.
|System||Minor or moderate overdose||Severe overdose|
A number of drug interactions can occur between MDMA and other drugs, including serotonergic drugs. MDMA also interacts with drugs which inhibit CYP450 enzymes, like ritonavir (Norvir), particularly CYP2D6 inhibitors. Concurrent use of MDMA high dosages with another serotonergic drug can result in a life-threatening condition called serotonin syndrome. Severe overdose resulting in death has also been reported in people who took MDMA in combination with certain monoamine oxidase inhibitors, such as phenelzine (Nardil), tranylcypromine (Parnate), or moclobemide (Aurorix, Manerix).
MDMA acts primarily as a presynaptic releasing agent of serotonin, norepinephrine, and dopamine, which arises from its activity at trace amine-associated receptor 1 (TAAR1) and vesicular monoamine transporter 2 (VMAT2). MDMA is also a monoamine transporter substrate (i.e., a substrate for DAT, NET, and SERT), so it enters monoamine neurons via these neuronal membrane transport proteins; by acting as a monoamine transporter substrate, MDMA produces competitive reuptake inhibition at the neuronal membrane transporters (i.e., it competes with endogenous monoamines for reuptake). MDMA inhibits both vesicular monoamine transporters (VMATs), the second of which (VMAT2) is highly expressed within monoamine neurons at vesicular membranes. Once inside a monoamine neuron, MDMA acts as a VMAT2 inhibitor and a TAAR1 agonist.
Inhibition of VMAT2 by MDMA results in increased concentrations of the associated neurotransmitter (serotonin, norepinephrine, or dopamine) in the cytosol of a monoamine neuron. Activation of TAAR1 by MDMA triggers protein kinase A and protein kinase C signaling events which then phosphorylates the associated monoamine transporters – DAT, NET, or SERT – of the neuron. In turn, these phosphorylated monoamine transporters either reverse transport direction – i.e., move neurotransmitters from the cytosol to the synaptic cleft – or withdraw into the neuron, respectively producing neurotransmitter efflux and noncompetitive reuptake inhibition at the neuronal membrane transporters. The actions increase the synaptic concentrations of monoamine neurotransmitters. MDMA has ten times more affinity for uptake at serotonin transporters compared to dopamine and norepinephrine transporters and consequently has mainly serotonergic effects.:1080
In summary, MDMA enters monoamine neurons by acting as a monoamine transporter substrate. MDMA activity at VMAT2 moves neurotransmitters out from synaptic vesicles and into the cytosol; MDMA activity at TAAR1 moves neurotransmitters out of the cytosol and into the synaptic cleft.
MDMA also has weak agonist activity at postsynaptic serotonin receptors 5-HT1 and 5-HT2 receptors, and its more efficacious metabolite MDA likely augments this action. Cortisol, prolactin, and oxytocin quantities in serum are increased by MDMA.
The MDMA concentration in the blood stream starts to rise after about 30 minutes, and reaches its maximal concentration in the blood stream between 1.5 and 3 hours after ingestion. It is then slowly metabolized and excreted, with levels of MDMA and its metabolites decreasing to half their peak concentration over the next several hours. The duration of action of MDMA is usually four to six hours, after which serotonin levels in the brain are depleted. Serotonin levels typically return to normal within 24–48 hours.
Metabolites of MDMA that have been identified in humans include 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 4-hydroxy-3-methoxyamphetamine (HMA), 3,4-dihydroxyamphetamine (DHA) (also called alpha-methyldopamine (α-Me-DA)), 3,4-methylenedioxyphenylacetone (MDP2P), and 3,4-Methylenedioxy-N-hydroxyamphetamine (MDOH). The contributions of these metabolites to the psychoactive and toxic effects of MDMA are an area of active research. 80% of MDMA is metabolised in the liver, and about 20% is excreted unchanged in the urine.
MDMA is known to be metabolized by two main metabolic pathways: (1) O-demethylenation followed by catechol-O-methyltransferase (COMT)-catalyzed methylation and/or glucuronide/sulfate conjugation; and (2) N-dealkylation, deamination, and oxidation to the corresponding benzoic acid derivatives conjugated with glycine. The metabolism may be primarily by cytochrome P450 (CYP450) enzymes CYP2D6 and CYP3A4 and COMT. Complex, nonlinear pharmacokinetics arise via autoinhibition of CYP2D6 and CYP2D8, resulting in zeroth order kinetics at higher doses. It is thought that this can result in sustained and higher concentrations of MDMA if the user takes consecutive doses of the drug.[non-primary source needed]
MDMA and metabolites are primarily excreted as conjugates, such as sulfates and glucuronides. MDMA is a chiral compound and has been almost exclusively administered as a racemate. However, the two enantiomers have been shown to exhibit different kinetics. The disposition of MDMA may also be stereoselective, with the S-enantiomer having a shorter elimination half-life and greater excretion than the R-enantiomer. Evidence suggests that the area under the blood plasma concentration versus time curve (AUC) was two to four times higher for the (R)-enantiomer than the (S)-enantiomer after a 40 mg oral dose in human volunteers. Likewise, the plasma half-life of (R)-MDMA was significantly longer than that of the (S)-enantiomer (5.8 ± 2.2 hours vs 3.6 ± 0.9 hours). However, because MDMA excretion and metabolism have nonlinear kinetics, the half-lives would be higher at more typical doses (100 mg is sometimes considered a typical dose).
MDMA is in the substituted methylenedioxyphenethylamine and substituted amphetamine classes of chemicals. As a free base, MDMA is a colorless oil insoluble in water. The most common salt of MDMA is the hydrochloride salt; pure MDMA hydrochloride is water-soluble and appears as a white or off-white powder or crystal.
There are numerous methods available to synthesize MDMA via different intermediates. The original MDMA synthesis described in Merck's patent involves brominating safrole to 1-(3,4-methylenedioxyphenyl)-2-bromopropane and then reacting this adduct with methylamine. Most illicit MDMA is synthesized using MDP2P (3,4-methylenedioxyphenyl-2-propanone) as a precursor. MDP2P in turn is generally synthesized from piperonal, safrole or isosafrole. One method is to isomerize safrole to isosafrole in the presence of a strong base, and then oxidize isosafrole to MDP2P. Another method uses the Wacker process to oxidize safrole directly to the MDP2P intermediate with a palladium catalyst. Once the MDP2P intermediate has been prepared, a reductive amination leads to racemic MDMA (an equal parts mixture of (R)-MDMA and (S)-MDMA). Relatively small quantities of essential oil are required to make large amounts of MDMA. The essential oil of Ocotea cymbarum, for example, typically contains between 80 and 94% safrole. This allows 500 ml of the oil to produce between 150 and 340 grams of MDMA.
Detection in body fluids
MDMA and MDA may be quantitated in blood, plasma or urine to monitor for use, confirm a diagnosis of poisoning or assist in the forensic investigation of a traffic or other criminal violation or a sudden death. Some drug abuse screening programs rely on hair, saliva, or sweat as specimens. Most commercial amphetamine immunoassay screening tests cross-react significantly with MDMA or its major metabolites, but chromatographic techniques can easily distinguish and separately measure each of these substances. The concentrations of MDA in the blood or urine of a person who has taken only MDMA are, in general, less than 10% those of the parent drug.
Early research and use
MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch. At the time, Merck was interested in developing substances that stopped abnormal bleeding. Merck wanted to avoid an existing patent held by Bayer for one such compound: hydrastinine. Köllisch developed a preparation of a hydrastinine analogue, methylhydrastinine, at the request of fellow lab members, Walther Beckh and Otto Wolfes. MDMA (called methylsafrylamin, safrylmethylamin or N-Methyl-a-Methylhomopiperonylamin in Merck laboratory reports) was an intermediate compound in the synthesis of methylhydrastinine. Merck was not interested in MDMA itself at the time. On 24 December 1912, Merck filed two patent applications that described the synthesis and some chemical properties of MDMA and its subsequent conversion to methylhydrastinine.
Merck records indicate its researchers returned to the compound sporadically. A 1920 Merck patent describes a chemical modification to MDMA. In 1927, Max Oberlin studied the pharmacology of MDMA while searching for substances with effects similar to adrenaline or ephedrine, the latter being structurally similar to MDMA. Compared to ephedrine, Oberlin observed that it had similar effects on vascular smooth muscle tissue, stronger effects at the uterus, and no "local effect at the eye". MDMA was also found to have effects on blood sugar levels comparable to high doses of ephedrine. Oberlin concluded that the effects of MDMA were not limited to the sympathetic nervous system. Research was stopped "particularly due to a strong price increase of safrylmethylamine", which was still used as an intermediate in methylhydrastinine synthesis. Albert van Schoor performed simple toxicological tests with the drug in 1952, most likely while researching new stimulants or circulatory medications. After pharmacological studies, research on MDMA was not continued. In 1959, Wolfgang Fruhstorfer synthesized MDMA for pharmacological testing while researching stimulants. It is unclear if Fruhstorfer investigated the effects of MDMA in humans.
Outside of Merck, other researchers began to investigate MDMA. In 1953 and 1954, the United States Army commissioned a study of toxicity and behavioral effects in animals injected with mescaline and several analogues, including MDMA. Conducted at the University of Michigan in Ann Arbor, these investigations were declassified in October 1969 and published in 1973. A 1960 Polish paper by Biniecki and Krajewski describing the synthesis of MDMA as an intermediate was the first published scientific paper on the substance.
MDMA may have been in non-medical use in the western United States in 1968. An August 1970 report at a meeting of crime laboratory chemists indicates MDMA was being used recreationally in the Chicago area by 1970. MDMA likely emerged as a substitute for its analog methylenedioxyamphetamine (MDA), a drug at the time popular among users of psychedelics which was made a Schedule 1 substance in the United States in 1970.
American chemist and psychopharmacologist Alexander Shulgin reported he synthesized MDMA in 1965 while researching methylenedioxy compounds at Dow Chemical Company, but did not test the psychoactivity of the compound at this time. Around 1970, Shulgin sent instructions for N-methylated MDA (MDMA) synthesis to the founder of a Los Angeles chemical company who had requested them. This individual later provided these instructions to a client in the Midwest. Shulgin may have suspected he played a role in the emergence of MDMA in Chicago.
Shulgin first heard of the psychoactive effects of N-methylated MDA around 1975 from a young student who reported "amphetamine-like content". Around 30 May 1976, Shulgin again heard about the effects of N-methylated MDA, this time from a graduate student in a medicinal chemistry group he advised at San Francisco State University who directed him to the University of Michigan study. She and two close friends had consumed 100 mg of MDMA and reported positive emotional experiences. Following the self-trials of a colleague at the University of San Francisco, Shulgin synthesized MDMA and tried it himself in September and October 1976. Shulgin first reported on MDMA in a presentation at a conference in Bethesda, Maryland in December 1976. In 1978, he and David E. Nichols published a report on the drug's psychoactive effect in humans. They described MDMA as inducing "an easily controlled altered state of consciousness with emotional and sensual overtones" comparable "to marijuana, to psilocybin devoid of the hallucinatory component, or to low levels of MDA".
While not finding his own experiences with MDMA particularly powerful, Shulgin was impressed with the drug's disinhibiting effects and thought it could be useful in therapy. Believing MDMA allowed users to strip away habits and perceive the world clearly, Shulgin called the drug "window". Shulgin occasionally used MDMA for relaxation, referring to it as "my low-calorie martini", and gave the drug to friends, researchers, and others who he thought could benefit from it. One such person was Leo Zeff, a psychotherapist who had been known to use psychedelic substances in his practice. When he tried the drug in 1977, Zeff was impressed with the effects of MDMA and came out of his semi-retirement to promote its use in therapy. Over the following years, Zeff traveled around the United States and occasionally to Europe, eventually training an estimated four thousand psychotherapists in the therapeutic use of MDMA. Zeff named the drug "Adam", believing it put users in a state of primordial innocence.
Psychotherapists who used MDMA believed the drug eliminated the typical fear response and increased communication. Sessions were usually held in the home of the patient or the therapist. The role of the therapist was minimized in favor of patient self-discovery accompanied by MDMA induced feelings of empathy. Depression, substance abuse, relationship problems, premenstrual syndrome, and autism were among several psychiatric disorders MDMA assisted therapy was reported to treat. According to psychiatrist George Greer, therapists who used MDMA in their practice were impressed by the results. Anecdotally, MDMA was said to greatly accelerate therapy. According to David Nutt, MDMA was widely used in the western US in couples counseling, and was called "empathy". Only later was the term "ecstasy" used for it, coinciding with rising opposition to its use.
Rising recreational use
In the late 1970s and early 1980s, "Adam" spread through personal networks of psychotherapists, psychiatrists, users of psychedelics, and yuppies. Hoping MDMA could avoid criminalization like LSD and mescaline, psychotherapists and experimenters attempted to limit the spread of MDMA and information about it while conducting informal research. Early MDMA distributors were deterred from large scale operations by the threat of possible legislation. Between the 1970s and the mid-1980s, this network of MDMA users consumed an estimated 500,000 doses.
A small recreational market for MDMA developed by the late 1970s, consuming perhaps 10,000 doses in 1976. By the early 1980s MDMA was being used in Boston and New York City nightclubs such as Studio 54 and Paradise Garage. Into the early 1980s, as the recreational market slowly expanded, production of MDMA was dominated by a small group of therapeutically minded Boston chemists. Having commenced production in 1976, this "Boston Group" did not keep up with growing demand and shortages frequently occurred.
Perceiving a business opportunity, Michael Clegg, the Southwest distributor for the Boston Group, started his own "Texas Group" backed financially by Texas friends. In 1981, Clegg had coined "Ecstasy" as a slang term for MDMA to increase its marketability. Starting in 1983, the Texas Group mass-produced MDMA in a Texas lab or imported it from California and marketed tablets using pyramid sales structures and toll-free numbers. MDMA could be purchased via credit card and taxes were paid on sales. Under the brand name "Sassyfras", MDMA tablets were sold in brown bottles. The Texas Group advertised "Ecstasy parties" at bars and discos, describing MDMA as a "fun drug" and "good to dance to". MDMA was openly distributed in Austin and Dallas–Fort Worth area bars and nightclubs, becoming popular with yuppies, college students, and gays.
Recreational use also increased after several cocaine dealers switched to distributing MDMA following experiences with the drug. A California laboratory that analyzed confidentially submitted drug samples first detected MDMA in 1975. Over the following years the number of MDMA samples increased, eventually exceeding the number of MDA samples in the early 1980s. By the mid-1980s, MDMA use had spread to colleges around the United States.:33
Media attention and scheduling
In an early media report on MDMA published in 1982, a Drug Enforcement Administration (DEA) spokesman stated the agency would ban the drug if enough evidence for abuse could be found. By mid-1984, MDMA use was becoming more noticed. Bill Mandel reported on "Adam" in a 10 June San Francisco Chronicle article, but misidentified the drug as methyloxymethylenedioxyamphetamine (MMDA). In the next month, the World Health Organization identified MDMA as the only substance out of twenty phenethylamines to be seized a significant number of times.
After a year of planning and data collection, MDMA was proposed for scheduling by the DEA on 27 July 1984 with a request for comments and objections. The DEA was surprised when a number of psychiatrists, psychotherapists, and researchers objected to the proposed scheduling and requested a hearing. In a Newsweek article published the next year, a DEA pharmacologist stated that the agency had been unaware of its use among psychiatrists. An initial hearing was held on 1 February 1985 at the DEA offices in Washington, D.C. with administrative law judge Francis L. Young presiding. It was decided there to hold three more hearings that year: Los Angeles on 10 June, Kansas City, Missouri on 10–11 July, and Washington, D.C. on 8–11 October.
Sensational media attention was given to the proposed criminalization and the reaction of MDMA proponents, effectively advertising the drug. In response to the proposed scheduling, the Texas Group increased production from 1985 estimates of 30,000 tablets a month to as many as 8,000 per day, potentially making two million ecstasy tablets in the months before MDMA was made illegal. By some estimates the Texas Group distributed 500,000 tablets per month in Dallas alone. According to one participant in an ethnographic study, the Texas Group produced more MDMA in eighteen months than all other distribution networks combined across their entire histories. By May 1985, MDMA use was widespread in California, Texas, southern Florida, and the northeastern United States. According to the DEA there was evidence of use in twenty-eight states and Canada. Urged by Senator Lloyd Bentsen, the DEA announced an emergency Schedule I classification of MDMA on 31 May 1985. The agency cited increased distribution in Texas, escalating street use, and new evidence of MDA (an analog of MDMA) neurotoxicity as reasons for the emergency measure. The ban took effect one month later on 1 July 1985 in the midst of Nancy Reagan's "Just Say No" campaign.
As a result of several expert witnesses testifying that MDMA had an accepted medical usage, the administrative law judge presiding over the hearings recommended that MDMA be classified as a Schedule III substance. Despite this, DEA administrator John C. Lawn overruled and classified the drug as Schedule I. Later Harvard psychiatrist Lester Grinspoon sued the DEA, claiming that the DEA had ignored the medical uses of MDMA, and the federal court sided with Grinspoon, calling Lawn's argument "strained" and "unpersuasive", and vacated MDMA's Schedule I status. Despite this, less than a month later Lawn reviewed the evidence and reclassified MDMA as Schedule I again, claiming that the expert testimony of several psychiatrists claiming over 200 cases where MDMA had been used in a therapeutic context with positive results could be dismissed because they weren't published in medical journals. No double blind studies had yet been conducted as to the efficacy of MDMA for therapy. In 2017 the FDA granted breakthrough therapy designation for its use with psychotherapy for PTSD.
While engaged in scheduling debates in the United States, the DEA also pushed for international scheduling. In 1985 the World Health Organization's Expert Committee on Drug Dependence recommended that MDMA be placed in Schedule I of the 1971 United Nations Convention on Psychotropic Substances. The committee made this recommendation on the basis of the pharmacological similarity of MDMA to previously scheduled drugs, reports of illicit trafficking in Canada, drug seizures in the United States, and lack of well-defined therapeutic use. While intrigued by reports of psychotherapeutic uses for the drug, the committee viewed the studies as lacking appropriate methodological design and encouraged further research. Committee chairman Paul Grof dissented, believing international control was not warranted at the time and a recommendation should await further therapeutic data. The Commission on Narcotic Drugs added MDMA to Schedule I of the convention on 11 February 1986.
The use of MDMA in Texas clubs declined rapidly after criminalization, although by 1991 the drug remained popular among young middle-class whites and in nightclubs.:46 In 1985, MDMA use became associated with Acid House on the Spanish island of Ibiza.:50 Thereafter in the late 1980s, the drug spread alongside rave culture to the UK and then to other European and American cities.:50 Illicit MDMA use became increasingly widespread among young adults in universities and later, in high schools. Since the mid-1990s, MDMA has become the most widely used amphetamine-type drug by college students and teenagers.:1080 MDMA became one of the four most widely used illicit drugs in the US, along with cocaine, heroin, and cannabis. According to some estimates as of 2004, only marijuana attracts more first time users in the US.
After MDMA was criminalized, most medical use stopped, although some therapists continued to prescribe the drug illegally. Later,[when?] Charles Grob initiated an ascending-dose safety study in healthy volunteers. Subsequent legally-approved MDMA studies in humans have taken place in the US. in Detroit (Wayne State University), Chicago (University of Chicago), San Francisco (UCSF and California Pacific Medical Center), Baltimore (NIDA–NIH Intramural Program), and South Carolina, as well as in Switzerland (University Hospital of Psychiatry, Zürich), the Netherlands (Maastricht University), and Spain (Universitat Autònoma de Barcelona).
In 2010, the BBC reported that use of MDMA had decreased in the UK in previous years. This may be due to increased seizures during use and decreased production of the precursor chemicals used to manufacture MDMA. Unwitting substitution with other drugs, such as mephedrone and methamphetamine, as well as legal alternatives to MDMA, such as BZP, MDPV, and methylone, are also thought to have contributed to its decrease in popularity.
According to David Nutt, when safrole was restricted by the United Nations in order to reduce the supply of MDMA, producers in China began using anethole instead, but this gives para-methoxyamphetamine (PMA, also known as "Dr Death"), which is much more toxic than MDMA and can cause overheating, muscle spasms, seizures, unconsciousness, and death. People wanting MDMA are sometimes sold PMA instead.
Society and culture
MDMA is legally controlled in most of the world under the UN Convention on Psychotropic Substances and other international agreements, although exceptions exist for research and limited medical use. In general, the unlicensed use, sale or manufacture of MDMA are all criminal offences.
In Australia, MDMA was declared an illegal substance in 1986 because of its harmful effects and potential for abuse. It is classed as a Schedule 9 Prohibited Substance in the country, meaning it is available for scientific research purposes only. Any other type of sale, use or manufacture is strictly prohibited by law. Permits for research uses on humans must be approved by a recognized ethics committee on human research.
In Western Australia under the Misuse of Drugs Act 1981 4.0g of MDMA is the amount required determining a court of trial, 2.0g is considered a presumption with intent to sell or supply and 28.0g is considered trafficking under Australian law.
In the United Kingdom, MDMA was made illegal in 1977 by a modification order to the existing Misuse of Drugs Act 1971. Although MDMA was not named explicitly in this legislation, the order extended the definition of Class A drugs to include various ring-substituted phenethylamines. The drug is therefore illegal to sell, buy, or possess without a licence in the UK. Penalties include a maximum of seven years and/or unlimited fine for possession; life and/or unlimited fine for production or trafficking.
Some researchers such as David Nutt have criticized the current scheduling of MDMA, which he determines to be a relatively harmless drug. An editorial he wrote in the Journal of Psychopharmacology, where he compared the risk of harm for horse riding (1 adverse event in 350) to that of ecstasy (1 in 10,000) resulted in his dismissal as well as the resignation of his colleagues from the ACMD.
In the United States, MDMA is currently placed in Schedule I of the Controlled Substances Act. In a 2011 federal court hearing, the American Civil Liberties Union successfully argued that the sentencing guideline for MDMA/ecstasy is based on outdated science, leading to excessive prison sentences. Other courts have upheld the sentencing guidelines. The United States District Court for the Eastern District of Tennessee explained its ruling by noting that "an individual federal district court judge simply cannot marshal resources akin to those available to the Commission for tackling the manifold issues involved with determining a proper drug equivalency."
In the Netherlands, the Expert Committee on the List (Expertcommissie Lijstensystematiek Opiumwet) issued a report in June 2011 which discussed the evidence for harm and the legal status of MDMA, arguing in favor of maintaining it on List I.
In Canada, MDMA is listed as a Schedule 1 as it is an analogue of amphetamine. The CDSA was updated as a result of the Safe Streets and Communities Act changing amphetamines from Schedule III to Schedule I in March 2012.
In 2014, 3.5% of 18 to 25 year-olds had used MDMA in the United States. In the European Union as of 2018, 4.1% of adults (15–64 years old) have used MDMA at least once in their life, and 0.8% had used it in the last year. Among young adults, 1.8% had used MDMA in the last 1.8% year.
In Europe, an estimated 37% of regular club-goers aged 14 to 35 used MDMA in the past year according to the 2015 European Drug report. The highest one-year prevalence of MDMA use in Germany in 2012 was 1.7% among people aged 25 to 29 compared with a population average of 0.4%. Among adolescent users in the United States between 1999 and 2008, girls were more likely to use MDMA than boys.
In 2008 the European Monitoring Centre for Drugs and Drug Addiction noted that although there were some reports of tablets being sold for as little as €1, most countries in Europe then reported typical retail prices in the range of €3 to €9 per tablet, typically containing 25–65 mg of MDMA. By 2014 the EMCDDA reported that the range was more usually between €5 and €10 per tablet, typically containing 57–102 mg of MDMA, although MDMA in powder form was becoming more common.
The United Nations Office on Drugs and Crime stated in its 2014 World Drug Report that US ecstasy retail prices range from US$1 to $70 per pill, or from $15,000 to $32,000 per kilogram. A new research area named Drug Intelligence aims to automatically monitor distribution networks based on image processing and machine learning techniques, in which an Ecstasy pill picture is analyzed to detect correlations among different production batches. These novel techniques allow police scientists to facilitate the monitoring of illicit distribution networks.
As of October 2015[update], most of the MDMA in the United States is produced in British Columbia, Canada and imported by Canada-based Asian transnational criminal organizations. The market for MDMA in the United States is relatively small compared to methamphetamine, cocaine, and heroin. In the United States, about 0.9 million people used ecstasy in 2010.
MDMA is particularly expensive in Australia, costing A$15–A$30 per tablet. In terms of purity data for Australian MDMA, the average is around 34%, ranging from less than 1% to about 85%. The majority of tablets contain 70–85 mg of MDMA. Most MDMA enters Australia from the Netherlands, the UK, Asia, and the US.
Corporate logos on pills
A number of ecstasy manufacturers brand their pills with a logo, often being the logo of an unrelated corporation. Some pills depict logos of products or shows popular with children, such as Shaun the Sheep.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is funding pilot studies and clinical trials investigating the use of MDMA in psychotherapy to treat posttraumatic stress disorder (PTSD), social anxiety in autistic adults, and anxiety in terminal illness. In November 2016, the United States Food and Drug Administration (FDA) approved large-scale phase 3 clinical trials involving the use of MDMA for the treatment of PTSD in individuals who do not respond to traditional prescription drugs or psychotherapy. MDMA has also been proposed as an adjunct to substance abuse treatment. In 2017, doctors in the UK began the first clinical study of MDMA in alcohol addiction.
The potential for MDMA to be used as a rapid-acting antidepressant has been studied in clinical trials, but as of 2017 the evidence on efficacy and safety were insufficient to reach a conclusion. A 2014 review of the safety and efficacy of MDMA as a treatment for various disorders, particularly PTSD, indicated that MDMA has therapeutic efficacy in some patients; however, it emphasized that issues regarding the controlability of MDMA-induced experiences and neurochemical recovery must be addressed. The author noted that oxytocin and D-cycloserine are potentially safer co-drugs in PTSD treatment, albeit with limited evidence of efficacy. This review and a second corroborating review by a different author both concluded that, because of MDMA's demonstrated potential to cause lasting harm in humans (e.g., serotonergic neurotoxicity and persistent memory impairment), "considerably more research must be performed" on its efficacy in PTSD treatment to determine if the potential treatment benefits outweigh its potential to harm to a patient.
- The term MDMA is a contraction of 3,4-methylenedioxy-methamphetamine; it is also known as ecstasy (shortened to "E", "X", or "XTC"), mandy, and molly.
- The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.
- "FDA Substance Registration System". United States National Library of Medicine. Retrieved 31 August 2017.
- Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 375. ISBN 978-0-07-148127-4.
- Betzler F, Viohl L, Romanczuk-Seiferth N (January 2017). "Decision-making in chronic ecstasy users: a systematic review". The European Journal of Neuroscience. 45 (1): 34–44. doi:10.1111/ejn.13480. PMID 27859780.
...the addictive potential of MDMA itself is relatively small.
- Jerome L, Schuster S, Yazar-Klosinski BB (March 2013). "Can MDMA play a role in the treatment of substance abuse?". Current Drug Abuse Reviews. 6 (1): 54–62. doi:10.2174/18744737112059990005. PMID 23627786.
Animal and human studies demonstrate moderate abuse liability for MDMA, and this effect may be of most concern to those treating substance abuse disorders.
- Palmer RB (2012). Medical toxicology of drug abuse : synthesized chemicals and psychoactive plants. Hoboken, N.J.: John Wiley & Sons. p. 139. ISBN 978-0-471-72760-6.
- "Methylenedioxymethamphetamine (MDMA or 'Ecstasy')". EMCDDA. European Monitoring Centre for Drugs and Drug Addiction. Retrieved 17 October 2014.
- "Methylenedioxymethamphetamine (MDMA, ecstasy)". Drugs and Human Performance Fact Sheets. National Highway Traffic Safety Administration. Archived from the original on 3 May 2012.
- Luciano RL, Perazella MA (June 2014). "Nephrotoxic effects of designer drugs: synthetic is not better!". Nature Reviews. Nephrology. 10 (6): 314–24. doi:10.1038/nrneph.2014.44. PMID 24662435.
- "DrugFacts: MDMA (Ecstasy or Molly)". National Institute on Drug Abuse. Archived from the original on 3 December 2014. Retrieved 2 December 2014.
- Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos M (August 2012). "Toxicity of amphetamines: an update". Archives of Toxicology. 86 (8): 1167–231. doi:10.1007/s00204-012-0815-5. PMID 22392347.
- Freye E (28 July 2009). "Pharmacological Effects of MDMA in Man". Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Springer Netherlands. pp. 151–160. doi:10.1007/978-90-481-2448-0_24. ISBN 978-90-481-2448-0.
- "3,4-Methylenedioxymethamphetamine". Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014.
- Meyer JS (2013). "3,4-methylenedioxymethamphetamine (MDMA): current perspectives". Substance Abuse and Rehabilitation. 4: 83–99. doi:10.2147/SAR.S37258. PMC 3931692. PMID 24648791.
- Anderson L, ed. (18 May 2014). "MDMA". Drugs.com. Drugsite Trust. Archived from the original on 23 March 2016. Retrieved 30 March 2016.
- "DrugFacts: MDMA (Ecstasy/Molly)". National Institute on Drug Abuse. February 2016. Archived from the original on 23 March 2016. Retrieved 30 March 2016.
- Freye E (2009). Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs: A comprehensive review on their mode of action, treatment of abuse and intoxication. Springer Science & Business Media. p. 147. ISBN 978-90-481-2448-0.
- Patel V (2010). Mental and neurological public health a global perspective (1st ed.). San Diego, CA: Academic Press/Elsevier. p. 57. ISBN 978-0-12-381527-9. Archived from the original on 10 September 2017.
- Philipps D (1 May 2018). "Ecstasy as a Remedy for PTSD? You Probably Have Some Questions". The New York Times. Retrieved 14 July 2018.
- Feduccia AA, Holland J, Mithoefer MC (February 2018). "Progress and promise for the MDMA drug development program". Psychopharmacology. 235 (2): 561–571. doi:10.1007/s00213-017-4779-2. PMID 29152674.
- Schwitzer G (13 May 2016). "CBS proclaims 'cancer breakthrough' – doesn't explain what FDA means by that term". Health News Review. Retrieved 9 October 2017.
- Kepplinger EE (February 2015). "FDA's Expedited Approval Mechanisms for New Drug Products". Biotechnology Law Report. 34 (1): 15–37. doi:10.1089/blr.2015.9999. PMC 4326266. PMID 25713472.
- "Fact Sheet: Breakthrough Therapies". United States Food and Drug Administration. 10 December 2014. Archived from the original on 9 October 2017. Retrieved 9 October 2017.
A breakthrough therapy is a drug:
• intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and
• preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
- Wan W (26 August 2017). "Ecstasy could be 'breakthrough' therapy for soldiers, others suffering from PTSD". Washington Post. Archived from the original on 29 August 2017. Retrieved 29 August 2017.
- Freudenmann RW, Öxler F, Bernschneider-Reif S (August 2006). "The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents" (PDF). Addiction. 101 (9): 1241–1245. doi:10.1111/j.1360-0443.2006.01511.x. PMID 16911722.
Although MDMA was, in fact, first synthesized at Merck in 1912, it was not tested pharmacologically because it was only an unimportant precursor in a new synthesis for haemostatic substances.
- World Health Organization (2004). Neuroscience of Psychoactive Substance Use and Dependence. World Health Organization. pp. 97–. ISBN 978-92-4-156235-5. Archived from the original on 28 April 2016.
- World Drug Report 2018 (PDF). United Nations. June 2018. p. 7. ISBN 978-92-1-148304-8. Retrieved 14 July 2018.
- "MDMA (Ecstasy/Molly)". National Institute on Drug Abuse. Retrieved 14 July 2018.
- Liechti ME, Gamma A, Vollenweider FX (March 2001). "Gender differences in the subjective effects of MDMA". Psychopharmacology. 154 (2): 161–8. doi:10.1007/s002130000648. PMID 11314678.
- Greene SL, Kerr F, Braitberg G (October 2008). "Review article: amphetamines and related drugs of abuse". Emergency Medicine Australasia. 20 (5): 391–402. doi:10.1111/j.1742-6723.2008.01114.x. PMID 18973636.
- Landriscina F (1995). "MDMA and the states of Consciousness". Eleusis. 2: 3–9.
- Baggott MJ, Kirkpatrick MG, Bedi G, de Wit H (June 2015). "Intimate insight: MDMA changes how people talk about significant others". Journal of Psychopharmacology. 29 (6): 669–77. doi:10.1177/0269881115581962. PMC 4698152. PMID 25922420.
- Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME (September 2014). "Differential effects of MDMA and methylphenidate on social cognition" (PDF). Journal of Psychopharmacology. 28 (9): 847–56. doi:10.1177/0269881114542454. PMID 25052243.
- Wardle MC, de Wit H (October 2014). "MDMA alters emotional processing and facilitates positive social interaction". Psychopharmacology. 231 (21): 4219–29. doi:10.1007/s00213-014-3570-x. PMC 4194242. PMID 24728603.
- Bravo GL (2001). "What does MDMA feel like?". In Holland J (ed.). Ecstasy: The complete guide. A comprehensive look at the risks and benefits of MDMA. Rochester: Park Street Press.
- Metzner R (2005). "Psychedelic, Psychoactive, and Addictive Drugs and States of Consciousness". In Earleywine M (ed.). Mind-Altering Drugs: The Science of Subjective Experience. New York: Oxford University.
- Kamilar-Britt P, Bedi G (October 2015). "The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals". Neuroscience and Biobehavioral Reviews. 57: 433–46. doi:10.1016/j.neubiorev.2015.08.016. PMC 4678620. PMID 26408071.
- Reynolds S (1999). Generation Ecstasy: Into the World of Techno and Rave Culture. Routledge. p. 81. ISBN 978-0-415-92373-6.
- McCrady BS, Epstein EE, eds. (2013). Addictions: a comprehensive guidebook (Second ed.). Oxford: Oxford University Press. p. 299. ISBN 978-0-19-975366-6.
- Capuzzi D, Gross DR, eds. (21 November 2014). Youth at Risk: A Prevention Resource for Counselors, Teachers, and Parents. John Wiley & Sons. p. 379. ISBN 978-1-119-02694-5.
- Sessa B, Nutt D (January 2015). "Making a medicine out of MDMA". The British Journal of Psychiatry. 206 (1): 4–6. doi:10.1192/bjp.bp.114.152751. PMID 25561485.
- Ebrahimian Z, Karimi Z, Khoshnoud MJ, Namavar MR, Daraei B, Haidari MR (1 February 2017). "Behavioral and Stereological Analysis of the Effects of Intermittent Feeding Diet on the Orally Administrated MDMA ("ecstasy") in Mice". Innovations in Clinical Neuroscience. 14 (1–2): 40–52. PMC 5373794. PMID 28386520.
MDMA is listed as a Schedule 1 drug by the United States Drug Enforcement Agency, meaning that currently there are no accepted medical uses for MDMA in the United States, there is a lack of accepted safety for use under medical supervision, and there is a high potential for abuse.
- Climko RP, Roehrich H, Sweeney DR, Al-Razi J (1986). "Ecstacy: a review of MDMA and MDA". International Journal of Psychiatry in Medicine. 16 (4): 359–72. doi:10.2190/dcrp-u22m-aumd-d84h. PMID 2881902.
- Freye E, Levy JV (2009). Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs a comprehensive review on their mode of action, treatment of abuse and intoxication (Online-Ausg. ed.). Dordrecht: Springer Netherlands. p. 152. ISBN 978-90-481-2448-0.
- Zarembo A (15 March 2014). "Exploring therapeutic effects of MDMA on post-traumatic stress". Los Angeles Times. Los Angeles Times. Retrieved 22 February 2015.
- MDMA and Religion. CSP. Retrieved on 11 June 2011.
- Watson L, Beck J (1991). "New age seekers: MDMA use as an adjunct to spiritual pursuit". Journal of Psychoactive Drugs. 23 (3): 261–70. doi:10.1080/02791072.1991.10471587. PMID 1685513.
- "MDMA (3,4-Methylenedioxymethamphetamine)" (PDF). 2015 National Drug Threat Assessment Summary. Drug Enforcement Administration. United States Department of Justice: Drug Enforcement Administration. October 2015. pp. 85–88. Retrieved 10 April 2016.
- Molly Madness. Drugs, Inc. (TV documentary). National Geographic Channel. 13 August 2014. ASIN B00LIC368M.
- Manic Molly. Drugs, Inc. (TV documentary). National Geographic Channel. 10 December 2014. ASIN B00LIC368M.
- Keane M (February 2014). "Recognising and managing acute hyponatraemia". Emergency Nurse. 21 (9): 32–6, quiz 37. doi:10.7748/en2014.02.21.9.32.e1128. PMID 24494770.
- White CM (March 2014). "How MDMA's pharmacology and pharmacokinetics drive desired effects and harms". Journal of Clinical Pharmacology. 54 (3): 245–52. doi:10.1002/jcph.266. PMID 24431106.
- Spauwen LW, Niekamp AM, Hoebe CJ, Dukers-Muijrers NH (February 2015). "Drug use, sexual risk behaviour and sexually transmitted infections among swingers: a cross-sectional study in The Netherlands". Sexually Transmitted Infections. 91 (1): 31–6. doi:10.1136/sextrans-2014-051626. PMID 25342812.
It is known that some recreational drugs (eg, MDMA or GHB) may hamper the potential to ejaculate or maintain an erection.
- "3,4-Methylenedioxymethamphetamine". Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014.
- Hahn I (25 March 2015). "MDMA Toxicity: Background, Pathophysiology, Epidemiology". Medscape. Retrieved 14 May 2016.
- Parrott AC (2012). "13. MDMA and LSD". In Verster J, Brady K, Galanter M, Conrod P (eds.). Drug Abuse and Addiction in Medical Illness: Causes, Consequences and Treatment. Springer Science & Business Media. p. 179. ISBN 978-1-4614-3375-0.
- Garg A, Kapoor S, Goel M, Chopra S, Chopra M, Kapoor A, McCann UD, Behera C (2015). "Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review". Current Drug Abuse Reviews. 8 (1): 15–25. doi:10.2174/1874473708666150303115833. PMID 25731754.
- Mueller F, Lenz C, Steiner M, Dolder PC, Walter M, Lang UE, Liechti ME, Borgwardt S (March 2016). "Neuroimaging in moderate MDMA use: A systematic review". Neuroscience and Biobehavioral Reviews. 62: 21–34. doi:10.1016/j.neubiorev.2015.12.010. PMID 26746590.
- Gouzoulis-Mayfrank E, Daumann J (2009). "Neurotoxicity of drugs of abuse--the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines". Dialogues in Clinical Neuroscience. 11 (3): 305–17. PMC 3181923. PMID 19877498.
- Halpin LE, Collins SA, Yamamoto BK (February 2014). "Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine". Life Sciences. 97 (1): 37–44. doi:10.1016/j.lfs.2013.07.014. PMC 3870191. PMID 23892199.
In contrast, MDMA produces damage to serotonergic, but not dopaminergic axon terminals in the striatum, hippocampus, and prefrontal cortex (Battaglia et al., 1987, O'Hearn et al., 1988). The damage associated with Meth and MDMA has been shown to persist for at least 2 years in rodents, non-human primates and humans (Seiden et al., 1988, Woolverton et al., 1989, McCann et al., 1998, Volkow et al., 2001a, McCann et al., 2005)
- Szigeti, Balázs; Winstock, Adam R; Erritzoe, David; Maier, Larissa J (7 May 2018). "Are ecstasy induced serotonergic alterations overestimated for the majority of users?". Journal of Psychopharmacology. 32 (7): 741–748. doi:10.1177/0269881118767646. PMID 29733742.
Given the dose-response relationship between MDMA exposure and SERT reductions and the statistically non-significant SERT binding differences for users with use levels similar to the majority of real-life users, it can be speculated that SERT levels may not be significantly affected for most recreational ecstasy users.
- Roberts CA, Jones A, Montgomery C (April 2016). "Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users". Neuroscience and Biobehavioral Reviews. 63: 158–67. doi:10.1016/j.neubiorev.2016.02.003. PMID 26855234.
- Parrott AC (2014). "The potential dangers of using MDMA for psychotherapy". Journal of Psychoactive Drugs. 46 (1): 37–43. doi:10.1080/02791072.2014.873690. PMID 24830184.
- Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, Zawada A, Somerville M (January 2009). "The harmful health effects of recreational ecstasy: a systematic review of observational evidence" (PDF). Health Technology Assessment. 13 (6): iii–iv, ix–xii, 1–315. doi:10.3310/hta13050. PMID 19195429.
- Kuypers KP, Theunissen EL, van Wel JH, de Sousa Fernandes Perna EB, Linssen A, Sambeth A, Schultz BG, Ramaekers JG (2016). "Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective". PLOS ONE. 11 (2): e0149438. Bibcode:2016PLoSO..1149438K. doi:10.1371/journal.pone.0149438. PMC 4764468. PMID 26907605.
- Laws KR, Kokkalis J (August 2007). "Ecstasy (MDMA) and memory function: a meta-analytic update". Human Psychopharmacology. 22 (6): 381–8. doi:10.1002/hup.857. PMID 17621368.
- Kousik SM, Napier TC, Carvey PM (2012). "The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation". Frontiers in Pharmacology. 3: 121. doi:10.3389/fphar.2012.00121. PMC 3386512. PMID 22754527.
- McMillan B, Starr C (2014). Human biology (10th ed.). Belmont, CA: Brooks/Cole Cengage Learning. ISBN 978-1-133-59916-6.
- Boyle NT, Connor TJ (September 2010). "Methylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern?". British Journal of Pharmacology. 161 (1): 17–32. doi:10.1111/J.1476-5381.2010.00899.X. PMC 2962814. PMID 20718737.
- Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831. Lay summary – Scientists want new drug rankings, BBC News (23 March 2007).
- Vorhees CV (November 1997). "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins". Drug and Chemical Toxicology. 20 (4): 387–99. doi:10.3109/01480549709003895. PMID 9433666.
- Meamar R, Karamali F, Sadeghi HM, Etebari M, Nasr-Esfahani MH, Baharvand H (June 2010). "Toxicity of ecstasy (MDMA) towards embryonic stem cell-derived cardiac and neural cells". Toxicology in Vitro. 24 (4): 1133–8. doi:10.1016/j.tiv.2010.03.005. PMID 20230888.
In summary, MDMA is a moderate teratogen that could influence cardiac and neuronal differentiation in the ESC model and these results are in concordance with previous in vivo and in vitro models.
- Singer LT, Moore DG, Fulton S, Goodwin J, Turner JJ, Min MO, Parrott AC (2012). "Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy". Neurotoxicology and Teratology. 34 (3): 303–10. doi:10.1016/j.ntt.2012.02.001. PMC 3367027. PMID 22387807.
- Olausson P, Jentsch JD, Tronson N, Neve RL, Nestler EJ, Taylor JR (September 2006). "DeltaFosB in the nucleus accumbens regulates food-reinforced instrumental behavior and motivation". The Journal of Neuroscience. 26 (36): 9196–204. doi:10.1523/JNEUROSCI.1124-06.2006. PMID 16957076.
- Robison AJ, Nestler EJ (October 2011). "Transcriptional and epigenetic mechanisms of addiction". Nature Reviews. Neuroscience. 12 (11): 623–37. doi:10.1038/nrn3111. PMC 3272277. PMID 21989194.
- Mack AH, Brady KT, Miller SI, Frances RJ (12 May 2016). Clinical Textbook of Addictive Disorders. Guilford Publications. p. 169. ISBN 978-1-4625-2169-2.
MDMA's addictive liability appears to be lower than that of other drugs of abuse....
- Favrod-Coune T, Broers B (July 2010). "The Health Effect of Psychostimulants: A Literature Review". Pharmaceuticals. 3 (7): 2333–2361. doi:10.3390/ph3072333. PMC 4036656. PMID 27713356.
It seems to present a smaller addiction potential than cocaine or methamphetamine.
- Ries R, Miller SC, Fiellin DA (2009). Principles of addiction medicine (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 226. ISBN 978-0-7817-7477-2.
MDA and MDMA are less reinforcing than amphetamine...
- Steinkellner T, Freissmuth M, Sitte HH, Montgomery T (January 2011). "The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine". Biological Chemistry. 392 (1–2): 103–15. doi:10.1515/BC.2011.016. PMC 4497800. PMID 21194370.
...approximately 15% of routine MDMA users recently fit the diagnostic criteria for MDMA dependence according to the Diagnostic and Statistical Manual, fourth edition/DSMIV.
- Mack AH, Brady KT, Miller SI, Frances RJ (12 May 2016). Clinical Textbook of Addictive Disorders. Guilford Publications. p. 171. ISBN 978-1-4625-2169-2.
There are no known pharmacological treatments for MDMA addiction.
- Vanattou-Saïfoudine N, McNamara R, Harkin A (November 2012). "Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators". British Journal of Pharmacology. 167 (5): 946–59. doi:10.1111/j.1476-5381.2012.02065.x. PMC 3492978. PMID 22671762.
- Hall AP, Henry JA (June 2006). "Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management". British Journal of Anaesthesia. 96 (6): 678–85. doi:10.1093/bja/ael078. PMID 16595612.
- de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J (April 2004). "Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition". Therapeutic Drug Monitoring. 26 (2): 137–44. doi:10.1097/00007691-200404000-00009. PMID 15228154.
It is known that some recreational drugs (e.g., MDMA or GHB) may hamper the potential to ejaculate or maintain an erection.
- Kellum JA, Gunn SR, Singer M (2008). Oxford American Handbook of Critical Care. Oxford University Press. p. 464. ISBN 978-0-19-530528-9. OCLC 1003197730.
- de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J (April 2004). "Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition". Therapeutic Drug Monitoring. 26 (2): 137–44. doi:10.1097/00007691-200404000-00009. PMID 15228154.
- Chummun H, Tilley V, Ibe J (2010). "3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition". British Journal of Nursing. 19 (2): 94–100. PMID 20235382.
- Pendergraft WF, Herlitz LC, Thornley-Brown D, Rosner M, Niles JL (November 2014). "Nephrotoxic effects of common and emerging drugs of abuse". Clinical Journal of the American Society of Nephrology. 9 (11): 1996–2005. doi:10.2215/CJN.00360114. PMC 4220747. PMID 25035273.
- Silins E, Copeland J, Dillon P (August 2007). "Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk". The Australian and New Zealand Journal of Psychiatry. 41 (8): 649–55. doi:10.1080/00048670701449237. PMID 17620161.
- Vuori E, Henry JA, Ojanperä I, Nieminen R, Savolainen T, Wahlsten P, Jäntti M (March 2003). "Death following ingestion of MDMA (ecstasy) and moclobemide". Addiction. 98 (3): 365–8. doi:10.1046/j.1360-0443.2003.00292.x. PMID 12603236.
- Miller GM (January 2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry. 116 (2): 164–76. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.
- "Midomafetamine". DrugBank. University of Alberta. 2 May 2018. Retrieved 15 May 2018.
It enters neurons via carriage by the monoamine transporters. Once inside, MDMA inhibits the vesicular monoamine transporter, which results in increased concentrations of serotonin, norepinephrine, and dopamine into the cytoplasm, and induces their release by reversing their respective transporters through a process known as phosphorylation.
- Berry MD, Gainetdinov RR, Hoener MC, Shahid M (December 2017). "Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges". Pharmacology & Therapeutics. 180: 161–180. doi:10.1016/j.pharmthera.2017.07.002. PMID 28723415.
As described above, a number of psychotropic agents including amphetamine, methamphetamine, and MDMA are potent agonists at human TAAR1 (Bunzow et al., 2001; Simmler et al., 2016). The subsequently observed regulatory effect of TAAR1 on dopaminergic systems has further strengthened this interest, given their well-documented involvement in reward circuitry.
- Fitzgerald JL, Reid JJ (November 1990). "Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices". European Journal of Pharmacology. 191 (2): 217–20. doi:10.1016/0014-2999(90)94150-V. PMID 1982265.
- Bogen IL, Haug KH, Myhre O, Fonnum F (2003). "Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo". Neurochemistry International. 43 (4–5): 393–400. doi:10.1016/S0197-0186(03)00027-5. PMID 12742084.
- Kalant H (2 October 2001). "The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs". Canadian Medical Association Journal. 165 (7): 917–28. PMC 81503. PMID 11599334.
- Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE (2011). Goldfrank's toxicologic emergencies (9th ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-160593-9.
- Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (April 1988). "Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites". European Journal of Pharmacology. 149 (1–2): 159–63. doi:10.1016/0014-2999(88)90056-8. PMID 2899513.
- Lyon RA, Glennon RA, Titeler M (1986). "3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors". Psychopharmacology. 88 (4): 525–6. doi:10.1007/BF00178519. PMID 2871581.
- Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA (August 1994). "Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors". Neuroscience Letters. 177 (1–2): 111–5. doi:10.1016/0304-3940(94)90057-4. PMID 7824160.
- Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (June 2003). "3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro". Molecular Pharmacology. 63 (6): 1223–9. doi:10.1124/mol.63.6.1223. PMID 12761331.
- Matsumoto RR (July 2009). "Targeting sigma receptors: novel medication development for drug abuse and addiction". Expert Review of Clinical Pharmacology. 2 (4): 351–8. doi:10.1586/ecp.09.18. PMC 3662539. PMID 22112179.
- Mas, M; Farré, M; de la Torre, R; Roset, PN; Ortuño, J; Segura, J; Camí, J (July 1999). "Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 136–45. PMID 10381769.
- Carrie LE, Donald F (March 1991). "A 26-gauge pencil-point needle for combined-epidural anaesthesia for caesarean section". Anaesthesia. 46 (3): 230–1. doi:10.1046/j.1365-2125.2000.00121.x. PMC 2014905. PMID 10671903.
- de la Torre R, Farré M, Roset PN, Lopez CH, Mas M, Ortuño J, Menoyo E, Pizarro N, Segura J, Cami J (September 2000). "Pharmacology of MDMA in humans". Annals of the New York Academy of Sciences. 914 (1): 225–37. Bibcode:2000NYASA.914..225D. doi:10.1111/j.1749-6632.2000.tb05199.x. PMID 11085324.
- Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (June 2008). "Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults". Therapeutic Drug Monitoring. 30 (3): 320–32. doi:10.1097/FTD.0b013e3181684fa0. PMC 2663855. PMID 18520604.
- Shima N, Kamata H, Katagi M, Tsuchihashi H, Sakuma T, Nemoto N (September 2007). "Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine". Journal of Chromatography B. 857 (1): 123–9. doi:10.1016/j.jchromb.2007.07.003. PMID 17643356.
- Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ (July 1999). "Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans". Clinical Chemistry. 45 (7): 1058–69. PMID 10388483.
- Mueller M, Peters FT, Maurer HH, McCann UD, Ricaurte GA (October 2008). "Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses". The Journal of Pharmacology and Experimental Therapeutics. 327 (1): 38–44. doi:10.1124/jpet.108.141366. PMID 18591215.
- Milhazes N, Martins P, Uriarte E, Garrido J, Calheiros R, Marques MP, Borges F (July 2007). "Electrochemical and spectroscopic characterisation of amphetamine-like drugs: application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors". Analytica Chimica Acta. 596 (2): 231–41. doi:10.1016/j.aca.2007.06.027. hdl:10316/45124. PMID 17631101.
- Milhazes N, Cunha-Oliveira T, Martins P, Garrido J, Oliveira C, Rego AC, Borges F (October 2006). "Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship". Chemical Research in Toxicology. 19 (10): 1294–304. doi:10.1021/tx060123i. hdl:10316/12872. PMID 17040098.
- Reductive aminations of carbonyl compounds with borohydride and borane reducing agents. Baxter, Ellen W.; Reitz, Allen B. Organic Reactions (Hoboken, New Jersey, United States) (2002), 59.
- Gimeno P, Besacier F, Bottex M, Dujourdy L, Chaudron-Thozet H (December 2005). "A study of impurities in intermediates and 3,4-methylenedioxymethamphetamine (MDMA) samples produced via reductive amination routes". Forensic Science International. 155 (2–3): 141–57. doi:10.1016/j.forsciint.2004.11.013. PMID 16226151.
- Palhol F, Boyer S, Naulet N, Chabrillat M (September 2002). "Impurity profiling of seized MDMA tablets by capillary gas chromatography". Analytical and Bioanalytical Chemistry. 374 (2): 274–81. doi:10.1007/s00216-002-1477-6. PMID 12324849.
- Renton RJ, Cowie JS, Oon MC (August 1993). "A study of the precursors, intermediates and reaction by-products in the synthesis of 3,4-methylenedioxymethylamphetamine and its application to forensic drug analysis". Forensic Science International. 60 (3): 189–202. doi:10.1016/0379-0738(93)90238-6. PMID 7901132.
- Mohan, J, ed. (June 2014). World Drug Report 2014 (PDF). Vienna, Austria: United Nations Office on Drugs and Crime. pp. 2, 3, 123–152. ISBN 978-92-1-056752-7. Retrieved 1 December 2014.
- Nov 2005 DEA Microgram newsletter, p. 166. Usdoj.gov (11 November 2005). Retrieved on 12 August 2013.
- Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther. Drug Monit. 30: 320–332, 2008.
- Barnes AJ, De Martinis BS, Gorelick DA, Goodwin RS, Kolbrich EA, Huestis MA (March 2009). "Disposition of MDMA and metabolites in human sweat following controlled MDMA administration" (PDF). Clinical Chemistry. 55 (3): 454–62. doi:10.1373/clinchem.2008.117093. PMC 2669283. PMID 19168553.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 9th edition, Biomedical Publications, Seal Beach, California, 2011, pp. 1078–1080.
- Bernschneider-Reif S, Oxler F, Freudenmann RW (November 2006). "The origin of MDMA ("ecstasy")--separating the facts from the myth". Die Pharmazie. 61 (11): 966–72. PMID 17152992.
- Firma E. Merck in Darmstadt (16 May 1914). "German Patent 274350: Verfahren zur Darstellung von Alkyloxyaryl-, Dialkyloxyaryl- und Alkylendioxyarylaminopropanen bzw. deren am Stickstoff monoalkylierten Derivaten". Kaiserliches Patentamt. Retrieved 12 April 2009.
- Firma E. Merck in Darmstadt (15 October 1914). "German Patent 279194: Verfahren zur Darstellung von Hydrastinin Derivaten". Kaiserliches Patentamt.
- Shulgin AT (1990). "1. History of MDMA". In Peroutka SJ (ed.). Ecstasy : the clinical, pharmacological, and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic Publishers. pp. 2, 14. ISBN 978-0-7923-0305-3.
- Hardman HF, Haavik CO, Seevers MH (June 1973). "Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals". Toxicology and Applied Pharmacology. 25 (2): 299–309. doi:10.1016/S0041-008X(73)80016-X. hdl:2027.42/33868. PMID 4197635.
- Benzenhöfer U, Passie T (August 2010). "Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin". Addiction. 105 (8): 1355–61. doi:10.1111/j.1360-0443.2010.02948.x. PMID 20653618.
- Biniecki S, Krajewski E (1960). "Production of d,1-N-methyl-beta-(3,4-methylenedioxyphenyl)-isopropylamine and d,1-N-methyl-beta-(3,4-dimthoxyphenyl)-isopropylamine". Acta Polon Pharm (in Polish). 17: 421–5.
- Siegel RK (October 1986). "MDMA. Nonmedical use and intoxication" (PDF). Journal of Psychoactive Drugs. 18 (4): 349–54. doi:10.1080/02791072.1986.10472368. PMID 2880950.
- The first confirmed sample was seized and identified by Chicago Police in 1970, see Sreenivasan VR (1972). "Problems in Identification of Methylenedioxy and Methoxy Amphetamines". Journal of Criminal Law, Criminology, and Police Science. 63 (2): 304–312. doi:10.2307/1142315. JSTOR 1142315.
- Foderaro LW (11 December 1988). "Psychedelic Drug Called Ecstasy Gains Popularity in Manhattan Nightclubs". The New York Times. The New York Times Company. Retrieved 27 August 2015.
- Brown E (September 2002). "Professor X". Wired. Retrieved 4 January 2015.
- Beck JE (April 1987). "Drug Abuse Series: MDMA". Erowid. Drug Abuse Information and Monitoring Project. Retrieved 6 August 2015.
- Pentney AR (2001). "An exploration of the history and controversies surrounding MDMA and MDA". Journal of Psychoactive Drugs. 33 (3): 213–21. doi:10.1080/02791072.2001.10400568. PMID 11718314.
- "Alexander 'Sasha' Shulgin". Alexander Shulgin Research Institute. Retrieved 8 January 2015.
- Shulgin A, Shulgin A (1991). "Chapters 12, 22". PiHKAL : A Chemical Love Story (7th printing, 1st ed.). Berkeley, CA: Transform Press. ISBN 978-0-9630096-0-9.
- Shulgin AT, Nichols DE (1978). "Characterization of Three New Psychotomimetics". In Willette, Robert E., Stillman, Richard Joseph (eds.). The Psychopharmacology of Hallucinogens. New York: Pergamon Press. pp. 74–83. ISBN 978-0-08-021938-7.
- Bennett, Drake (30 January 2005). "Dr. Ecstasy". New York Times Magazine.
- Jennings P (1 April 2004). "Ecstasy Rising". Primetime Thursday (Special edition). ABC News. Archived from the original on 27 May 2015.
- Shulgin A (2004). "Tribute to Jacob" (PDF). In Doblin R (ed.). The Secret Chief Revealed (2nd ed.). Sarasota, Fl: Multidisciplinary Association for Psychedelic Studies. pp. 17–18. ISBN 978-0-9660019-6-9. Retrieved 7 January 2015.
- Ecstasy on Prescription, BBC Business Daily, May 29, 2018.
- Eisner B (1994). Ecstasy : The MDMA Story (Expanded 2nd ed.). Berkeley, CA: Ronin Publishing. ISBN 978-0-914171-68-3.
- Beck J, Rosenbaum M (1994). "The Distribution of Ecstasy". Pursuit of Ecstasy : The MDMA Experience. Albany: State Univ. of New York Press. ISBN 978-0-7914-1817-8.
- Doblin R, Rosenbaum M (1991). "Chapter 6: Why MDMA Should Not Have Been Made Illegal" (PDF). In Inciardi JA (ed.). The Drug Legalization Debate (2nd ed.). London: Sage Publications, Inc. ISBN 978-0-8039-3678-2. Retrieved 10 August 2015.
- Collin M, Godfrey J (2010). "The Technologies of Pleasure". Altered State: The Story of Ecstasy Culture and Acid House (Updated new ed.). London: Profile Books. ISBN 978-1-84765-641-4.
- Savlov M (12 June 2000). "Countdown to Ecstasy: A New Drug for a New Millennium". The Austin Chronicle. Weekly Wire. Retrieved 6 August 2015.
- Owen F, Gavin L (20 October 2013). "Molly Isn't Who You Think She Is: A Deeper Look at MDMA". Playboy. Retrieved 6 August 2015.
- Sylvan R (2005). "A Brief History of the Rave Scene". Trance Formation: The Spiritual and Religious Dimensions of Global Rave Culture. New York, NY: Routledge. pp. 21–22. ISBN 978-0-415-97090-7.
- Parrott AC (May 2004). "Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity" (PDF). Psychopharmacology. 173 (3–4): 234–41. doi:10.1007/s00213-003-1712-7. PMID 15007594.
- Renfroe CL (October 1986). "MDMA on the street: Analysis Anonymous". Journal of Psychoactive Drugs. 18 (4): 363–9. doi:10.1080/02791072.1986.10472371. PMID 2880953.
- "Schedules of Controlled Substances Proposed Placement of 3,4-Methylenedioxymethamphetamine in Schedule I" (PDF). Federal Register. 49 (146): 30210. 27 July 1984. Retrieved 15 January 2015.
- Adler J, Abramson P, Katz S, Hager M (15 April 1985). "Getting High on 'Ecstasy'" (PDF). Newsweek Magazine. Life/Style. p. 96. Retrieved 1 February 2015.
- Holland J (2001). "The History of MDMA". In Holland J (ed.). Ecstasy: the complete guide; a comprehensive look at the risks and benefits of MDMA. Rochester, VT: Park Street Press. ISBN 978-0-89281-857-0.
- "U.S. will ban 'ecstasy,' a hallucinogenic drug". The New York Times. The Associated Press. 1 June 1985. Retrieved 29 April 2015.
- "MDMA – FDA REPORT, 1985". Erowid. Food and Drug Administration. 1985. Retrieved 11 August 2015.
- Baker K (30 May 1985). "DEA To Ban "Ecstasy" – The Drug MDMA". The Associated Press. Retrieved 7 August 2015.
- Corwin M (31 May 1985). "U.S. to Ban Use of Drug MDMA : Street Abuse Cited; Used by Psychiatrists". Los Angeles Times. Retrieved 11 August 2015.
- Weber B (7 June 2014). "Alexander Shulgin, Psychedelia Researcher, Dies at 88". The New York Times. The New York Times Company. Retrieved 28 August 2015.
- Vastag B (3 June 2014). "Chemist Alexander Shulgin, popularizer of the drug Ecstasy, dies at 88". The Washington Post. WP Company LLC. Retrieved 28 August 2015.
- "Ecstasy has its pros and cons". Kokomo Tribune. Kokomo, Indiana. Harper's Bazaar. 23 November 1985. p. 6 – via newspaperarchive.com.
- WHO Expert Committee on Drug Dependence: Twenty-second Report (PDF). Geneva: World Health Organization. 1985. pp. 24–25. ISBN 978-9241207294. Archived from the original (PDF) on 19 October 2014. Retrieved 29 August 2012.
- "Decision to place MDMA into Schedule I" (PDF). UNODC. Commission on Narcotic Drugs. 11 February 1986. Retrieved 9 May 2015.
- McKinley JC (12 September 2013). "Overdoses of 'Molly' Led to Electric Zoo Deaths". The New York Times. Retrieved 9 December 2013.
- Bibliography of Psychedelic Research Studies. collected by the Multidisciplinary Association for Psychedelic Studies Archived 3 December 2013 at the Wayback Machine
- James SD (23 February 2015). "What Is Molly and Why Is It Dangerous?". NBCNews.com. Retrieved 23 February 2015.
Why is it called Molly? That's short for "molecule." "You can put a ribbon and bow on it and call it a cute name like 'Molly' and people are all in," said Paul Doering, professor emeritus of pharmacology at the University of Florida.
- Aleksander I (21 June 2013). "Molly: Pure, but Not So Simple". The New York Times. The New York Times Company. Retrieved 24 February 2015.
- "Mephedrone (4-Methylmethcathinone) appearing in "Ecstasy" in the Netherlands". 19 September 2010. Retrieved 31 December 2012.
- "Why ecstasy is 'vanishing' from UK nightclubs". BBC News. 19 January 2010. Retrieved 14 February 2010.
- Bish J (4 August 2017). "Watch Out for Pentylone, the Horrible New MDMA Additive". Vice.
- "Annual prevalence of use of drugs, by region and globally, 2016". World Drug Report 2018. United Nations Office on Drugs and Crime. 2018. Retrieved 7 July 2018.
- "Misuse of Drugs Act 1981". The Government of Western Australia. Department of the Premier and Cabinet. 23 October 1981.
- Power M (2013). Drugs 2.0 : the web revolution that's changing how the world gets high (epub file). London: Portobello. ISBN 978-1-84627-459-6.
- Misuse of Drugs Act 1971. Statutelaw.gov.uk (5 January 1998). Retrieved on 11 June 2011.
- "Ecstasy 'no more dangerous than horse riding'". Telegraph.co.uk. Retrieved 4 December 2015.
- Nutt DJ (January 2009). "Equasy-- an overlooked addiction with implications for the current debate on drug harms". Journal of Psychopharmacology. 23 (1): 3–5. doi:10.1177/0269881108099672. PMID 19158127.
- Johnson A (2 November 2009). "Why Professor David Nutt was shown the door". The Guardian. London. Retrieved 3 November 2009.
- Schedules of Controlled Substances; Scheduling of 3,4-Methylenedioxymethamphetamine (MDMA) Into Schedule I of the Controlled Substances Act; Remand, 53 Fed. Reg. 5,156 (DEA 22 February 1988).
- Court Rejects Harsh Federal Drug Sentencing Guideline as Scientifically Unjustified | American Civil Liberties Union. Aclu.org (15 July 2011). Retrieved on 29 August 2012.
- Hennig AC (2014). "An Examination of Federal Sentencing Guidelines' Treatment of MDMA ('Ecstasy')". Belmont Law Review. 1: 267. SSRN 2481227.
- Rapport Drugs in Lijsten | Rapport. Rijksoverheid.nl (27 June 2011). Retrieved on 29 August 2012.
- "Committee: the current system of the Opium Act does not have to be changed". government.nl. 24 June 2011. Retrieved 29 August 2012.
- "Schedule I". Controlled Drugs and Substances Act. Isomer Design. Retrieved 9 December 2013.
- "Definitions and interpretations". Controlled Drugs and Substances Act. Isomer Design. Retrieved 9 December 2013.
- "Statistical Bulletin 2018 — prevalence of drug use | www.emcdda.europa.eu". www.emcdda.europa.eu. Retrieved 5 February 2019.
- Wu P, Liu X, Pham TH, Jin J, Fan B, Jin Z (November 2010). "Ecstasy use among US adolescents from 1999 to 2008". Drug and Alcohol Dependence. 112 (1–2): 33–8. doi:10.1016/j.drugalcdep.2010.05.006. PMC 2967577. PMID 20570447.
- European Monitoring Centre for Drugs and Drug Addiction (2008). Annual report: the state of the drugs problem in Europe (PDF). Luxembourg: Office for Official Publications of the European Communities. p. 49. ISBN 978-92-9168-324-6.
- "European Drug Report 2014, page 26" (PDF).
- "Ecstasy-type substances Retail and wholesale prices* and purity levels, by drug, region and country or territory". United Nations Office on Drugs and Crime. Archived from the original on 8 December 2015. Retrieved 2 January 2015.
- Camargo J, Esseiva P, González F, Wist J, Patiny L (November 2012). "Monitoring of illicit pill distribution networks using an image collection exploration framework". Forensic Science International. 223 (1–3): 298–305. doi:10.1016/j.forsciint.2012.10.004. PMID 23107059.
- Drugtext – 10 years of ecstasy and other party drug use in Australia: What have we done and what is there left to do?. Drugtext.org. Retrieved on 11 June 2011. Archived 9 February 2012 at the Wayback Machine
- "Erowid MDMA Vault : Images". Retrieved 3 March 2016.
- "Now sick dealers peddle Shaun the Sheep Ecstasy tablets". Western Daily Press. Archived from the original on 12 August 2015. Retrieved 3 March 2016.
- Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS (January 2016). "MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 64: 237–49. doi:10.1016/j.pnpbp.2015.03.011. PMID 25818246.
- Maxmen A. "Psychedelic Compound in Ecstasy Moves Closer to Approval to Treat PTSD". Scientific American. Retrieved 18 May 2017.
- Maxmen A (2017). "Psychedelic compound in ecstasy moves closer to approval to treat PTSD". Nature. doi:10.1038/nature.2017.21917. Retrieved 18 May 2017.
- Waldman A (10 January 2017). A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life. Knopf Doubleday Publishing Group. ISBN 978-0-451-49410-8. Retrieved 18 May 2017.
- Lattin D (19 March 2015). "Patients in ecstasy clinical trial find drug beneficial". San Francisco Chronicle. Hearst Corporation. Archived from the original on 24 April 2016. Retrieved 28 April 2016.
- Mithoefer MC, Grob CS, Brewerton TD (May 2016). "Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA". The Lancet. Psychiatry. 3 (5): 481–8. doi:10.1016/S2215-0366(15)00576-3. PMID 27067625.
- Philipps D (29 November 2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". The New York Times Company. The New York Times. Archived from the original on 6 January 2017. Retrieved 1 December 2016.
- Devlin H (30 June 2017). "World's first trials of MDMA to treat alcohol addiction set to begin". The Guardian.
- Patel R, Titheradge D (June 2015). "MDMA for the treatment of mood disorder: all talk no substance?". Therapeutic Advances in Psychopharmacology. 5 (3): 179–88. doi:10.1177/2045125315583786. PMC 4502590. PMID 26199721.
- MDMA Facts and Statistics National Institute on Drug Abuse
- Methylenedioxymethamphetamine (MDMA or 'Ecstasy') drug profile European Monitoring Centre for Drugs and Drug Addiction
- MDMA-Assisted Psychotherapy Multidisciplinary Association for Psychedelic Studies